AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference
The presentations will showcase how AC Immune’s expertise in discovery, assay development and characterization of promising candidates powers its industry-leading pipeline. Two oral presentations will highlight the Company’s first-in-class positron emission tomography (PET) imaging agent and therapeutic antibody programs targeting TDP-43 proteinopathies, and two electronic poster presentations will focus on AC Immune’s novel small molecule aggregation inhibitor and clinical-stage PET imaging agent for alpha-synuclein.
Prof.
Scientific updates at AD/PDTM 2021
Morphomer™ TDP-43 imaging
Title: Discovery of PET tracers for TDP-43 proteinopathies
Date:
Presenter: Oral presentation by Tamara Seredenina
Anti-TDP-43 antibody
Title: TDP-43 antibody directed microglial clearance and inhibition of seeded aggregation mitigates neuropathology in models of TDP-43 proteinopathy
Date:
Presenter: Oral presentation by
Morphomer™ alpha-synuclein imaging
Title: [18F]ACI-12589, a novel alpha-synuclein radiotracer as a biomarker in patients with Parkinson’s disease and other synucleinopathies
E-poster ID: P531 / #868
Presenter: E-poster presentation by
Morphomer™ alpha-synuclein small molecule aggregation inhibitor
Title: Generating a first-in-class inhibitor to treat Parkinson’s disease by targeting intracellular alpha-synuclein pathology
E-poster ID: P425 / #1195
Presenter: E-poster presentation by Nadine Aït-Bouziad
About
For further information, please contact:
Head of Investor Relations Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com |
US Media LaVoie Health Science Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com |
Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA